Stem definition | Drug id | CAS RN |
---|---|---|
monoclonal antibodies (humanized origin); interleukin and interleukin receptors | 5478 | 1418205-77-2 |
Molecule | Description |
---|---|
Synonyms:
|
Bimekizumab is a humanised IgG1/kappa monoclonal antibody that selectively binds with high affinity to IL-17A, IL-17F and IL-17AF cytokines, blocking their interaction with the IL-17RA/IL-17RC receptor complex. Elevated concentrations of IL-17A and IL-17F have been implicated in the pathogenesis of several immune-mediated inflammatory diseases including plaque psoriasis. Bimekizumab inhibits these proinflammatory cytokines, resulting in the normalization of skin inflammation and as a consequence improvement in clinical symptoms associated with psoriasis. From in vitro models, bimekizumab was shown to inhibit psoriasis-related gene expression and cytokine production to a greater extent than inhibition of IL-17A alone.
|
Dose | Unit | Route |
---|---|---|
5.70 | mg | P |
None
Date | Agency | Company | Orphan |
---|---|---|---|
Aug. 20, 2021 | EMA | UCB Pharma S.A. | |
Jan. 20, 2022 | PMDA | UCB JAPAN CO., LTD. |
None
None
None
None
Source | Code | Description |
---|---|---|
ATC | L04AC21 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS Interleukin inhibitors |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Plaque psoriasis | indication | 200965009 | |
Pustular psoriasis | indication | 200973000 | |
Erythrodermic psoriasis | indication | 200977004 | |
Inflammatory bowel disease | contraindication | 24526004 | DOID:0050589 |
Upper respiratory tract infection | contraindication | 54150009 | |
Oral candidiasis | contraindication | 79740000 | DOID:14262 |
Active tuberculosis | contraindication | 427099000 |
None
None
None
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Interleukin-17A | Cytokine | ANTIBODY BINDING | Kd | 11.46 | DRUG LABEL | DRUG LABEL | |||
Interleukin-17F | Cytokine | ANTIBODY BINDING | Kd | 10.55 | DRUG LABEL | DRUG LABEL | |||
Interleukin-17AF | Cytokine | ANTIBODY BINDING | Kd | 10.59 | DRUG LABEL | DRUG LABEL |
ID | Source |
---|---|
09495UIM6V | UNII |
C4519734 | UMLSCUI |
CHEMBL4297700 | ChEMBL_ID |
DB12917 | DRUGBANK_ID |
D11550 | KEGG_DRUG |
9878 | INN_ID |
9411 | IUPHAR_LIGAND_ID |
018864 | NDDF |
C000625981 | MESH_SUPPLEMENTAL_RECORD_UI |
None